资深专业团队,助力高产转化性研究

 

 

 

桐树基因搭建了以肿瘤进化论与肿瘤基因组学标本库为基础的转化性研究中心,从课题设计、研究执行(基因检测)、数据整理及挖掘、文章撰写、投稿修改,提供一站式转化性研究服务。

 

深谙肿瘤克隆进化论

 

 

 

桐树基因CTO蔡微菁以第一作者在肿瘤医学领域顶级期刊JCO上发表论文,提出了肿瘤克隆进化与驱动基因的关系,当期JCO邀请Charles Swanton教授配发封面述评推荐此研究!

Intratumoral Heterogeneity of ALK-Rearranged and
ALK/EGFR Coaltered Lung Adenocarcinoma

2018 Impact Factor : 28.245

 

J Clin Onco. l. 2015 Nov 10;33(32):3701-9. PMID: 26416997

Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered LADCs. Altered oncogenic drivers in spatially separated subclones of the same tumor may be different.

查看文章

临床转化性研究硕果累累

 

 

 

各项转化研究成果已被SCI高影响因子期刊收录,获国际权威杂志的广泛认可

至今发表SCI文章影响因子总和>120分

 

ROS1 fusions in Chinese patients with non-small-cell lung cancer

2018 Impact Factor : 14.196

 

Ann Oncol. 2013 Jul;24(7):1822-7. PMID: 23514723

ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive patients.

查看文章

Comprehensive Analysis of EGFRMutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations

2018 Impact Factor : 12.46

 

J Thorac Oncol. 2017 Sep;12(9):1388-1397. PMID: 28624467

The abundance of EGFR activating mutation by ARMS+ was significantly associated with objective response to EGFR-TKIs. The abundance of EGFRT790M mutation may have an adverse impact on PFS rather than ORR in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

查看文章